• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
How AI and real-world data are rewriting the rare disease playbook

How AI and real-world data are rewriting the rare disease playbook

by Truveta staff | Aug 18, 2025 | Data

After years of uncertainty, a recent policy change is sparking new optimism in rare disease drug development. A change in federal policy now keeps certain multi-indication rare therapies exempt from Medicare price negotiations—a rule that had discouraged some...
Truveta experts: Sudden cardiac arrest and arrhythmias among patients with chronic kidney disease

Truveta experts: Sudden cardiac arrest and arrhythmias among patients with chronic kidney disease

by Truveta staff | Aug 12, 2025 | Research

In this edition of Truveta experts, Esther Kim, PhD, MPH, Senior Director of Research Services at Truveta, shares findings from her recent exploration of the burden of sudden cardiac arrest (SCA) or sudden cardiac death (SCD), as well as cardiac arrhythmias, among...
Lyme disease peaks in June, remains high through August

Lyme disease peaks in June, remains high through August

by Truveta Research | Aug 1, 2025 | Research, Research Insights

62.7% of Lyme cases occurred between May and August, underscoring the heightened risk during late spring and summer. June consistently showed the highest activity, accounting for nearly 1 in 5 cases (19.4%) across observed years. Risk of Lyme remains elevated in...
Infection risk and adoption trends in hemodialysis catheters: New real-world evidence

Infection risk and adoption trends in hemodialysis catheters: New real-world evidence

by Truveta staff | Jul 31, 2025 | Research

Can catheter design impact patient safety? That’s the question of a new peer-reviewed study from Medical Components, Inc. (Medcomp), based on a retrospective analysis of 3,546 catheter insertions captured in Truveta Data. Used to deliver life-sustaining dialysis...
Truveta experts: Real-world trends in Rituxan biosimilar adoption

Truveta experts: Real-world trends in Rituxan biosimilar adoption

by Truveta staff | Jul 21, 2025 | Research

In this Truveta experts spotlight, Jared Kern and Vidya Venkataraman, PhD explored trends in the use of Rituxan biosimilars between 2018 and 2024. Their analysis of Truveta Data reveals how patient access and switching behavior has evolved over time. Jared Kern is a...
« Older Entries
Next Entries »

Share this


Recent posts

  • Real-world analysis links Dexcom CGM use to reduced progression of chronic kidney disease
  • Truveta experts: Gestational diabetes screening in real-world practice
  • Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.